CM Venture Capital Exclusively Leads Tens of Millions RMB A+ Round in Boea Wisdom to Advance Precision Cerebrovascular and Cardiovascular Therapeutics
Boea Wisdom
AI Simulation Technology Developer
Recently, CM Venture Capital officially announced that it had exclusively led a multi-million-yuan financing round for Boea Wisdom Technology Co., Ltd. (hereinafter referred to as “Boea Wisdom”). The funds from this Pre-A+ round will be fully allocated to the R&D and iterative development of core products, the advancement of multicenter clinical trials, commercialization efforts, and the building of an elite team. This investment aims to further strengthen Boea Wisdom’s technological barriers and market leadership in the field of precision diagnosis and treatment for vascular interventions, leveraging technology to illuminate the future of cardiovascular and cerebrovascular health.
01.
The Return of the Young Hearts: The Original Aspirations of a Group of Youths Forge the Light of Medical Innovation
Late one night in 2019, a transoceanic phone call from a vascular surgeon at a top-tier Chinese hospital pierced the tranquility of an overseas laboratory. A group of young Chinese scholars in the United States, deeply entrenched in the technology sector, held prestigious patents and enjoyed lucrative careers. Yet, driven by the conviction that “China’s diagnosis and treatment of cardiovascular and cerebrovascular diseases require more precise technologies,” they resolutely set aside their overseas accolades and returned to their homeland with patriotic devotion.
BOEA·WISDOM—this is the origin of the founding vision behind “Boea Wisdom.” BOEA, derived from a homophone of “boys,” embodies the passion and purity of young entrepreneurs striving side by side; WISDOM, signifying wisdom, carries the mission of empowering diagnosis and treatment through technology. These light-chasers, with sincere hearts and wise minds, have taken root in Hangzhou, embarking on an innovative journey that deeply integrates engineering numerical simulation, artificial intelligence, and clinical medicine.
Looking back on the journey, every step is engraved with perseverance and breakthrough:
● In June 2019, the company officially established its presence in Hangzhou, embarking on a journey of technological exploration;
● In January 2022, completed Pre-A round financing, injecting the initial capital momentum into R&D; ● In November 2023, obtained China’s first NMPA Class III medical device registration certificate for vascular interventional surgery planning software, with the core product DetecMicro® making its landmark market debut and filling a domestic technological gap;
● In July 2024, the procurement, training, and product deployment at the Third Hospital of Jilin University were successfully completed, marking the first critical step in commercialization.
● In 2025, the company successfully established five benchmark partner hospitals and achieved comprehensive strategic ecosystem cooperation with B2B enterprises such as Medtronic, Siemens, and GE, realizing scalable business growth. During the same period, it launched its flagship simulation software for vascular interventional device implantation and fully initiated clinical validation in collaboration with Academician Wang Jian’an’s team, further solidifying the company’s leading position in the industry.
From the laboratory to the clinical frontline, and from technological breakthroughs to market implementation, Boea Wisdom remains steadfast in its vision of “becoming a leading provider of digital simulation technologies for cardiovascular and cerebrovascular diseases.” Leveraging core technologies including Computational Fluid Dynamics (CFD), Computational Solid Mechanics (CSM), and AI-driven digital twins, the company rapidly constructs patient-specific vascular models to create comprehensive diagnostic and therapeutic solutions that cover the entire workflow—from image acquisition and preoperative planning to intraoperative navigation and postoperative monitoring. By collaborating with numerous top-tier tertiary hospitals in China, Boea Wisdom makes complex endovascular interventions safer and more precise, driving the comprehensive upgrade of cardiovascular and cerebrovascular diagnosis and treatment toward personalization, precision, and intelligence.
02.
Capital Empowerment: Hard-Tech Investment Safeguards the Path of Medical Innovation
CM Venture Capital, the lead investor in this round, is a science-driven venture capital firm deeply rooted in the field of transformative hard technologies. Since 2010, it has been established in China’s technology investment market, focusing on frontier sectors such as materials and resources, energy and power, and digitalization plus AI. Leveraging the professional insights of its multinational scientist team, global industrial resources, and rigorous investment philosophy, CM Venture Capital is committed to providing both financial and strategic empowerment to hard-tech enterprises.
The partnership between China Materialia and Boea Wisdom originated from their mutual collaboration with L'Oréal on the Big Bang project, where Boea Wisdom won L'Oréal’s 2024 Big Bang Award for its leading technology in AI-powered simulation. Traditional simulation computing is time-consuming, demands significant computational resources, and yields suboptimal results for modeling cardiovascular systems, which are under constant stress. Boea Wisdom’s core technology platform traces back to 2007, when its team proposed the principle of “reactive force simulation analysis” for cardiovascular applications, developing all underlying simulation software code independently. From consumer goods and industrial manufacturing to healthcare, Boea Wisdom’s faster and more efficient simulation technology has unlocked numerous new commercially viable scenarios. Among these, the sector of precision diagnosis and treatment for cerebrovascular and cardiovascular diseases stands out due to urgent clinical needs and broad industrial prospects. Leveraging its proprietary core technologies, Boea Wisdom has built a high-barrier product portfolio that combines technological maturity with significant clinical value, earning favor from industry leaders such as Siemens and Medtronic, and demonstrating immense growth potential. Moving forward, China Materialia will continue to leverage its capital and industrial resource advantages to fully support Boea Wisdom in accelerating technological innovation and market expansion, jointly building a new ecosystem for healthcare, and exploring applications beyond the medical field at the appropriate time.
03.
Journeying Across Mountains and Seas: With Innovation as Wings, Leading the Future of Medical Simulation
This round of financing marks another significant milestone in the development journey of Boea Wisdom, and even more so, a brand-new starting point. Embarking on this new chapter, this group of entrepreneurs, driven by their original aspirations, will continue to forge ahead with courage and determination. They will remain deeply committed to the field of precision diagnosis and treatment in vascular intervention, further integrating engineering technologies with clinical applications, and continuously refining their comprehensive technological ecosystem, including the Detec series, the Medi series, and vascular simulation quality control.
On the technical front, the company will continuously iterate its simulation algorithms and AI digital twin technologies, breaking through the precision and scenario boundaries of cardiovascular and cerebrovascular disease simulations, expanding into more diagnostic and therapeutic fields such as peripheral vascular and neurointerventional procedures, and building a globally leading digital simulation technology platform. On the commercial front, it will accelerate nationwide multi-center clinical deployment and commercialization, deepen collaborations with healthcare institutions and industry partners, and make precision diagnosis and treatment technologies accessible to more patients and frontline clinical practitioners.
With conviction in heart, we go far; with expertise in skill, we reach further. Boea Wisdom will take this financing round as an opportunity, using innovation as its sail and responsibility as its rudder, to scale new heights in the field of digital cardiovascular and cerebrovascular simulation. By harnessing the power of technology to reshape the landscape of diagnosis and treatment, we will inject robust momentum into the industry’s high-quality development and safeguard the lives and health of hundreds of millions of patients with cardiovascular and cerebrovascular diseases. Let the light of China’s smart healthcare illuminate every beating heart!
